N-((3-Benzyloxy-7-chloroquinolin-2-yl)carbonyl)glycine | 189360-06-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-((3-Benzyloxy-7-chloroquinolin-2-yl)carbonyl)glycine
• 英文别名: 2-[(7-Chloro-3-phenylmethoxyquinoline-2-carbonyl)amino]acetic acid
• CAS: 189360-06-3
• 化学式: C₁₉H₁₅ClN₂O₄
• 分子量: 370.792
• InChiKey: DYDWJNJGNNLBPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  88.5
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Medicaments for increasing endogenous erythropoietine (EPO)
  申请人：FIBROGEN, INC.

  公开号：EP2289531A2

  公开（公告）日：2011-03-02

  The present invention relates to compounds for use in methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Compounds for use in methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included.

  本发明涉及用于通过在体外和体内增加内源性促红细胞生成素来治疗促红细胞生成素相关疾病的方法的化合物。本发明还包括用于治疗、预处理或预调节或预防促红细胞生成素相关疾病的化合物。
• Medicaments for increasing endogenous Erythropoietin (EPO)
  申请人：Fibrogen, Inc.

  公开号：EP2298301A2

  公开（公告）日：2011-03-23

  The present invention relates to compounds for use in methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Compounds for use in methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included.

  本发明涉及用于通过在体外和体内增加内源性促红细胞生成素来治疗促红细胞生成素相关疾病的方法的化合物。本发明还包括用于治疗、预处理或预调节或预防促红细胞生成素相关疾病的化合物。
• HIF PROLYL HYDROXYLASE INHIBITOR FOR TREATMENT OF ANEMIA
  申请人：Fibrogen, Inc.

  公开号：EP3520784A1

  公开（公告）日：2019-08-07

  The present invention relates to methods for treating anemia by increasing endogenous erythropoietin via inhibition of HIF prolyl hydroxylase enzyme activity.

  本发明涉及通过抑制 HIF 丙氨酰羟化酶活性增加内源性促红细胞生成素来治疗贫血的方法。
• EP1463823A4
  申请人：——

  公开号：EP1463823A4

  公开（公告）日：2005-11-16
• METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO)
  申请人：FibroGen, Inc.

  公开号：EP1463823A2

  公开（公告）日：2004-10-06